Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Home Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

/ Publications

Share the Post

About the Author

Related Posts

Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT
Mohammad Hirmand, MD
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Read More
Richard Maroun, JD

Comments

Comments are closed.